NCT02561884View on ClinicalTrials.gov

A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Healthy
Interventions
DRUG

Olostar Tab.

DRUG

Co-administration of Olmetec and Crestor

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT02561884 - A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers | Biotech Hunter | Biotech Hunter